预约演示
更新于：2026-10-23
Nitrazepam
硝西泮
更新于：2026-10-23
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H11N3O3 |
InChIKeyKJONHKAYOJNZEC-UHFFFAOYSA-N |
CAS号146-22-5 |
关联
6
项与 硝西泮 相关的临床试验JPRN-jRCT1061220093
Validation of concomitant medications affecting lamotrigine blood levels
EUCTR2013-004936-31-NL
Establish limits for fitness to drive with prolonged use of ICADTS class III medication
IRCT2013092414552N4
Nitrazepam versus Diazepam as intermittent prophylaxis for febrile seizures
100 项与 硝西泮 相关的临床结果
登录后查看更多信息
100 项与 硝西泮 相关的转化医学
登录后查看更多信息
100 项与 硝西泮 相关的专利（医药）
登录后查看更多信息
2,610
项与 硝西泮 相关的文献（医药）2026-11-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Validation of qualitative and quantitative methods for 40 benzodiazepines and Z-drugs in hair by UPLC-MS/MS
Article
作者: Zhao, Junbo ; Yan, Hui ; Yu, Shujie ; Yan, Fang ; Zhang, Miao ; Xiang, Ping
In recent years, the analysis and identification of benzodiazepines and Z-drugs have presented significant challenges in forensic medicine and pharmaceutical analysis due to their widespread use. Notably, some of these substances are classified as new psychoactive substances (NPS) by the UNODC. Hair was chosen as a biological matrix for monitoring long-term drug intake in this study. We aimed to develop and validate a rapid and sensitive method for simultaneous determination of 40 benzodiazepines and Z-drugs in hair using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). All the analytes were detected within 11 min. The method was validated with linear calibration curves over the range of 5-500 pg mg-1 (coefficient of determination, r2 > 0.99). The limits of detection (LOD) were 1-3 pg mg-1, and the limits of quantification (LOQ) were 5 pg mg-1. The method demonstrated acceptable selectivity, accuracy, and precision (< 20%). Matrix effects ranged from -29.8-23.5%, and recoveries ranged from 77.9% to 119.9%. The method was successfully applied to six authentic hair samples, detecting nine substances: Nitrazepam, Temazepam, Lorazepam, 7-Aminoflunitrazepam, Clobazam, Lormetazepam, α-Hydroxyalprazolam, 7-Aminoclonazepam, and Zolpidem. Benzodiazepines concentrations ranged from 5.6 to 436.1 pg mg-1, while zolpidem concentrations ranged from 11.1 to 113.8 pg mg-1. This method provided a reliable tool for detecting benzodiazepines and Z-drugs in hair and addresses the requirements of routine forensic practice.
2026-05-01PSYCHIATRY AND CLINICAL NEUROSCIENCES
Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta‐analysis
Review
作者: Sakuma, Kenji ; Kishi, Taro ; Ikuta, Toshikazu ; Hatano, Masakazu ; Kitajima, Tsuyoshi ; Kishi, Tatsuhiko ; Iwata, Nakao
Aim:
This network meta‐analysis of randomized controlled trials (RCTs) aimed to investigate which hypnotics are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea.
Methods:
Primary outcomes included total sleep time (TST) and apnea–hypopnea index (AHI) during TST. Other outcomes were rapid eye movement (REM) sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI during non‐REM or REM sleep, mean peripheral oxygen saturation (SpO
2
) during TST, mean SpO
2
nadir during TST, arousal index (AI), all‐cause discontinuation, adverse event‐related discontinuation, and incidence of individual adverse events. Effect sizes with 95% confidence intervals were calculated.
Results:
This systematic review included 32 RCTs (
n
= 1871, average age = 51.60 years, 62.52% male, mean AHI = 23.60). Our network meta‐analysis evaluated brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Compared with placebo, lemborexant increased TST, REM sleep time, and SE and decreased LPS and WASO, whereas both daridorexant and zolpidem increased TST and SE and decreased WASO. These three medications demonstrated respiratory safety and discontinuation profiles similar to those of placebo. Eszopiclone increased TST and SE and decreased LPS, WASO, AHI during TST, and AI, but its effects on LPS, WASO, AHI during TST, and AI disappeared in the sensitivity analysis, excluding continuous positive airway pressure titration studies.
Conclusion:
Our network meta‐analysis identified different effects of various hypnotics on sleep architecture and respiratory parameters; however, the lack of data prevented a formal synthesis of subjective outcomes. Therefore, these results should be interpreted with caution in clinical practice.
2026-03-01Annals of Palliative Medicine
Chronic schizophrenia with aggravation of psychiatric symptoms after cancer surgery: a case report and mini literature review
Review
作者: Matsuoka, Hiromichi ; Yamaguchi, Junji ; Wada, Saho ; Nakahara, Rika ; Nishikawa, Eri ; Terada, Tatsuto ; Sadahiro, Ryoichi
BACKGROUND:
Patients with cancer and comorbid psychiatric disorders, including schizophrenia, may experience aggravation of psychiatric symptoms during cancer treatment. Oncology hospitals without dedicated psychiatric wards sometimes face challenges in managing cases with severe psychiatric symptoms. Concerns exist that the worsening of psychiatric symptoms may lead to the interruption of cancer treatment.
CASE DESCRIPTION:
A woman in her 60s had chronic schizophrenia, with an estimated onset in her 20s. She had long been prescribed quetiapine (150 mg/day, oral), haloperidol (0.75 mg/day, oral), nitrazepam (10 mg/day, oral), and paroxetine (20 mg/day, oral). At X years, she was diagnosed with ovarian cancer and underwent surgery following discontinuation of the psychotropics. On day 2 after hospitalization, she became confused, hallucinatory, and delusional with severe agitation. Although initially stabilized, the patient exhibited worsening psychiatric symptoms again on day 7. Ultimately, the patient was mentally stabilized with adjusted doses of oral quetiapine (250 mg/day) and haloperidol (1.5 mg/day, oral) and was discharged on day 16. Thanks to the intervention, cancer treatment continued uninterrupted.
CONCLUSIONS:
Patients with comorbid schizophrenia and cancer may present severe psychiatric symptoms in the cancer perioperative period, even if schizophrenia is in a chronic phase. Postoperative delirium, withdrawal delirium, and exacerbation of schizophrenia were speculated to be the possible contributing factors in this case. When patients with cancer also have schizophrenia, oncologists and liaison psychiatrists need to carefully monitor their mental status to prevent interruptions in cancer treatment.
100 项与 硝西泮 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 日本 | 1967-02-25 | |
| 癫痫 | 日本 | 1967-02-25 | |
| 强直阵挛性癫痫 | 日本 | 1967-02-25 | |
| 入睡和睡眠障碍 | 日本 | 1967-02-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | benzodiazepine | 鏇廠繭憲製鑰艱衊鹽網 = 鬱醖網製糧鏇憲築齋鏇 鑰範艱選願醖夢壓襯糧 (鬱繭醖齋壓鹽簾遞蓋製, 願艱醖壓觸顧窪淵鹹淵 ~ 艱蓋網膚願齋廠鬱繭簾) 更多 | - | 2012-03-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用